X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
XMT-1536 (upifitamab rilsodotin) is a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, it delivers approximately 10 DolaLock payload molecules per antibody. It is being investigated for platinum-sensitive ovarian cancer.
Lead Product(s): Upifitamab Rilsodotin
Therapeutic Area: Oncology Product Name: XMT-1536
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
XMT-1536 (upifitamab rilsodotin) is a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, it delivers approximately 10 DolaLock payload molecules per antibody. It is being investigated for platinum-sensitive ovarian cancer.
Lead Product(s): Upifitamab Rilsodotin
Therapeutic Area: Oncology Product Name: XMT-1536
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
XMT-2056 is a systemically-administered immunosynthen STING agonist antibody drug conjugate (DAR 8) that is designed to target a novel HER2-high or -low tumors as a monotherapy or in combination with standard-of-care HER2 agents.
Lead Product(s): XMT-2056
Therapeutic Area: Oncology Product Name: XMT-2056
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
XMT-1536 (upifitamab rilsodotin) is a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, it delivers approximately 10 DolaLock payload molecules per antibody. It is being investigated for platinum-sensitive ovarian cancer.
Lead Product(s): Upifitamab Rilsodotin,Carboplatin
Therapeutic Area: Oncology Product Name: XMT-1536
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
XMT-2056 is an Immunosynthen STING agonist ADC that is designed to target a novel HER2 epitope and locally activate STING signaling in both tumor-resident immune cells and in tumor cells to provide the potential to treat patients with HER2 high or low tumors.
Lead Product(s): XMT-2056
Therapeutic Area: Oncology Product Name: XMT-2056
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
The Immunosynthen platform generates systemically administered Antibody-drug Conjugates that locally activate STING signaling in both tumor-resident immune cells and in antigen-expressing tumor cells, unlocking the anti-tumor potential of innate immune stimulation.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $830.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration December 22, 2022
Details:
Upifitamab Rilsodotin (UpRi, XMT-1536) is Mersana’s first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that is designed to enable a high drug-to-antibody ratio and controlled bystander effect.
Lead Product(s): Upifitamab Rilsodotin
Therapeutic Area: Oncology Product Name: XMT-1536
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
UpRi is Mersana’s first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that enables a high drug-to-antibody ratio and controlled bystander effect.
Lead Product(s): Upifitamab Rilsodotin
Therapeutic Area: Oncology Product Name: XMT-1536
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: IQVIA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
XMT-1660 is a B7-H4-directed Dolasynthen antibody drug conjugate with a precise, target-optimized drug-to-antibody ratio (DAR 6) and Mersana’s clinically validated DolaLock microtubule inhibitor payload with controlled bystander effect.
Lead Product(s): XMT-1660
Therapeutic Area: Oncology Product Name: XMT-1660
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
XMT-1660 is a B7-H4-directed Dolasynthen antibody drug conjugate with a precise, target-optimized drug-to-antibody ratio (DAR 6) and Mersana’s clinically validated DolaLock microtubule inhibitor payload with controlled bystander effect.
Lead Product(s): XMT-1660
Therapeutic Area: Oncology Product Name: XMT-1660
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
